SCHEMBL26998196

SCHEMBL26998196

CN(CCO)c1cc(-c2cn[nH]c2)c2ccc(Cl)c(Cl)c2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K14 Q99558 2/20 0.38
▸ PRKAB2 O43741 1/20 0.37
▸ PRKAG1 P54619 1/20 0.37
▸ PRKAA2 P54646 1/20 0.37
▸ PRKAA1 Q13131 1/20 0.37
▸ PRKAG3 Q9UGI9 1/20 0.37
▸ PRKAG2 Q9UGJ0 1/20 0.37
▸ PRKAB1 Q9Y478 1/20 0.37
▸ FGFR1 P11362 3/20 0.37
▸ FGFR2 P21802 3/20 0.37
▸ FGFR4 P22455 3/20 0.37
▸ FGFR3 P22607 3/20 0.37
▸ KDR P35968 3/20 0.37
▸ ROCK2 O75116 9/20 0.35
▸ ROCK1 Q13464 4/20 0.34
▸ PIM1 P11309 1/20 0.33
▸ PIM2 Q9P1W9 1/20 0.33
▸ TACR1 P25103 1/20 0.33
▸ TACR3 P29371 1/20 0.33
▸ STK4 Q13043 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26998207 0.94 MAP3K14 (0.37) MAP3K14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL26999118 0.89 PTPN11 (0.40) MAP3K14FGFR1FGFR2FGFR4FGFR3
SCHEMBL25424012 0.88 MAP3K14 (0.38) MAP3K14ROCK2ROCK1
SCHEMBL26998152 0.87 MAP3K14 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL26998160 0.87 MAP3K14 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL26998155 0.86 ROCK2 (0.36) MAP3K14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL26998153 0.85 ROCK2 (0.36) MAP3K14ROCK2ROCK1
SCHEMBL26998214 0.84 MAP3K14 (0.35) MAP3K14ROCK2ROCK1
SCHEMBL25427115 0.84 MAP3K14 (0.38) MAP3K14ROCK2ROCK1PIM1PIM2
SCHEMBL26999119 0.83 PIM1 (0.34) MAP3K14ROCK2ROCK1PIM1PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS MAP3K14 2494/4885PRKAB2 318/4885PRKAG1 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback